Castle Biosciences Revenue and Competitors

Friendswood, TX USA

Location

$354.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Castle Biosciences's estimated annual revenue is currently $53M per year.(i)
  • Castle Biosciences received $5.1M in venture funding in June 2018.
  • Castle Biosciences's estimated revenue per employee is $111,600
  • Castle Biosciences's total funding is $354.3M.

Employee Data

  • Castle Biosciences has 475 Employees.(i)
  • Castle Biosciences grew their employee count by 2% last year.

Castle Biosciences's People

NameTitleEmail/Phone
1
Product OwnerReveal Email/Phone
2
Product OwnerReveal Email/Phone
3
Executive Director, Business DevelopmentReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
VP SalesReveal Email/Phone
6
VP, Sales & MarketingReveal Email/Phone
7
VP R&DReveal Email/Phone
8
VP, ReimbursementReveal Email/Phone
9
SVP, R&DReveal Email/Phone
10
VP Medical AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Castle Biosciences?

Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. We have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future Please visit us at www.castlebiosciences.com for more information on our company and products.

keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Medical Diagnostics,Pharmaceuticals

$354.3M

Total Funding

475

Number of Employees

$53M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Castle Biosciences News

2022-04-17 - Castle Biosciences to Present Data at the 18th European ...

Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress. Poster presentations to highlight...

2022-04-17 - Weekly Research Analysts' Ratings Changes for Castle ...

Castle Biosciences (NASDAQ: CSTL) has recently received a number of price target changes and ratings updates: 4/14/2022 – Castle Biosciences...

2022-03-30 - Castle Biosciences snaps up San Diego's AltheaDx to push precision medicine into mental health

Castle Biosciences, which went public in 2019, makes tests that help guide treatment for certain cancers, including melanoma, squamous cell...

2021-11-09 - Castle Biosciences Announces Third Quarter 2021 Results - Form 8-K

Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p ...

2021-05-06 - Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program

LOS ANGELES (PRWEB) May 06, 2021 MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, today announced that Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer dia ...

Castle Biosciences Funding

DateAmountRoundLead InvestorsReference
2013-11-27$1.0MUndisclosedArticle
2014-08-14$11.8MUndisclosedHealthQuest CapitalArticle
2015-04-15$6.0MUndisclosedSilicon Valley BankArticle
2015-07-28$11.7MUndisclosedArticle
2016-03-15$14.0MUndisclosedSilicon Valley BankArticle
2017-05-10$20.0MUndisclosedOxford FinanceArticle
2018-06-15$5.1MUndisclosedArticle